"ASCO26: BMS and J&J debut shining multiple myeloma data" was originally created and published by Pharmaceutical Technology, ...

Teclistamab improved PFS, OS in patients who had received up to three previous lines of th ...

Advancements in chemotherapy and immunotherapy have improved multiple myeloma survival rates, with 5-year relative survival increasing from 37.7% to 60.3% between 2000-2004 and 2015-2019. Treatment ...

BMS Announces CELMoD Mezigdomide Reduces Risk of Disease Progression or Death by More than 50% vs. Standard of Care ...

BVd regimen showed significant OS improvement over DVd in relapsed/refractory multiple myeloma, with a predicted median OS of 84 months versus 51 months. BVd achieved higher ORR (83.1% vs 71.3%) and ...

RALEIGH, N.C. (WTVD) -- The American Cancer Society reports that the five-year relative cancer survival rate for all cancers combined hit 70% for people diagnosed between 2016-2021 in the United ...

Patients with newly diagnosed multiple myeloma (NDMM) treated at a specialized clinic have improved outcomes, with median overall survival (OS) of 152 months, according to a research letter published ...

Adding teclistamab to daratumumab dramatically improved progression-free survival and overall survival vs standard-of-care (SOC) therapy in patients with relapsed or refractory multiple myeloma (RRMM) ...